Apimeds Pharmaceuticals US, Inc (APUS) Stock Price & Analysis
Apimeds Pharmaceuticals US, Inc (APUS) — MoonshotScore 29/100 (Weak band), calculated Oct 26, 2026. Price $2.89 (-8.54%), as of the Oct 23, 2026 trading session; market cap $4.36M.
Educational signal · not a buy or sell recommendation · How to read this
Apimeds Pharmaceuticals US, Inc · APUS · NYSE
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Apitox, an active pharmaceutical ingredient. Apitox targets inflammation and pain management associated with osteoarthritis and multiple sclerosis.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore v2 · Apimeds Pharmaceuticals US (APUS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a strained balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.
Earnings yield is the main valuation drag relative to sector peers.
- Altman Z -2.09 · Piotroski F 1
- ROE -59.0% · ROA -45.6% · current ratio 0.51
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
The score was 29 in the stored Oct 24, 2026 snapshot and remains 29 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.89 | |
| Change on the day | -8.54% | |
| 52-week range | $1.51 – $59.70 | |
| Market capitalisation | $4.36M | |
| Shares traded on the day | 35.4K |
Price & events
Other perspectives
Council score for Apimeds Pharmaceuticals US (APUS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the APUS film — every key number, told as a short cinematic story
~2 min · open the film
What is Apimeds Pharmaceuticals US (APUS), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Apimeds Pharmaceuticals US, Inc (APUS) is listed on NYSE. It employs 7 people and is led by Vinod Menon. The market values it at $4.36M.
What are the financial strengths and risks for Apimeds Pharmaceuticals US (APUS)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -2.09 · Piotroski F 1. Trailing ratios: ROE -59.0% · ROA -45.6% · current ratio 0.51.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -2.09 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-59.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How is Apimeds Pharmaceuticals US scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
| Company | Price | Market value | Score |
|---|---|---|---|
| $16.65 Oct 26, 2026 | $88.5M | — Model unavailable | |
| $10.24 Oct 26, 2026 | $93.6M | — Model unavailable | |
| $4.08 Oct 26, 2026 | $170M | — Model unavailable | |
| $2.44 Oct 26, 2026 | $190M | — Model unavailable | |
| $8.45 Oct 26, 2026 | $252M | — Model unavailable | |
| $8.81 Oct 26, 2026 | $506M | — Model unavailable | |
| $9.53 Oct 26, 2026 | $566M | — Model unavailable | |
| $3.85 Oct 26, 2026 | $570M | — Model unavailable | |
| $7.94 Oct 26, 2026 | $612M | — Model unavailable | |
| $11.90 Oct 26, 2026 | $793M | — Model unavailable | |
| $4.20 Oct 26, 2026 | $832M | — Model unavailable | |
| $9.18 Oct 26, 2026 | $885M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Apimeds Pharmaceuticals US Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the APUS research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for APUS?
APUS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Apitox, an active pharmaceutical ingredient.
Is APUS a good stock to buy?
Stock Expert AI does not rate APUS buy, sell or hold. Apimeds Pharmaceuticals US, Inc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the APUS stock price today?
The last price recorded on this page for Apimeds Pharmaceuticals US, Inc (APUS) is $2.89, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for APUS?
The main risks for Apimeds Pharmaceuticals US, Inc. include the potential failure to obtain regulatory approval for Apitox, competition from established pharmaceutical companies with greater resources, and adverse clinical trial results that could halt development of Apitox.
What are the key factors to evaluate for APUS?
Apimeds Pharmaceuticals US, Inc (APUS) holds a MoonshotScore in the low range. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc. Not financial advice.
How frequently does APUS data refresh on this page?
APUS's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven APUS's recent stock price performance?
Apimeds Pharmaceuticals US, Inc (APUS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific active pharmaceutical ingredient (Apitox). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider APUS overvalued or undervalued right now?
Apimeds Pharmaceuticals US, Inc (APUS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of APUS?
Fractional-share availability for Apimeds Pharmaceuticals US, Inc (APUS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 6 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $2.89 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T07:24:32.764Z. | |
px.change | Change on the day | -8.54% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $4.36M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T19:59:53.000Z. Captured from FMP at 2026-10-26T07:24:31.700Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.27 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 35.4K | FMP | Financial Modeling Prep (FMP) · quote | |
own.insiders | Insider transactions via FMP | 12 transactions · 0 purchases, 0 sales, 12 other transactions · 7 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z -2.09 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -59.0% · ROA -45.6% · current ratio 0.51 | — | UNRECORDED | Stored key metrics — Date unknown |
px.range52 | 52-week range | $1.51 – $59.70 | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
id.employees | Employees | 7 | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation | |
id.ceo | Chief executive | Vinod Menon | UNRECORDED | Stored company-profile observation — Captured 2026-10-19 · Expired observation |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 29 of 100 · Weak · pillars 27 / 27 / 11 / 17 / 14 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.valuation_driver | Recorded valuation score driver | Earnings yield is the main valuation drag relative to sector peers. | OURS | Stock Expert AI MoonshotScore v2 engine · stored factor contributions | |
ours.moonshot_change | MoonshotScore movement | 29 (stored snapshot Oct 24, 2026) → 29 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.